All In Biotech

Drug Trial Radar · NCT06911320

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of Bemnifosbuvir and Ruzasvir Administered as a Fixed-Dose Combination in Adult Participants With Severe Renal or Hepatic Impairment in Comparison to Healthy Participants

Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Apr 9, 2025

Primary completion

Apr 30, 2026

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Atea Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Apr 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose

Conditions

  • Healthy Volunteer Study
  • Hepatic Impairment
  • Renal Impairment

Interventions

  • Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combinationDrug

    A single dose of BEM/RZR will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) of BEM/RZR Maximum plasma concentration (Cmax)Time frame: Day 1
  2. Pharmacokinetics (PK) of BEM/RZR Area under the plasma concentration-time curve (AUC)Time frame: Day 1
  3. Pharmacokinetics (PK) of BEM/RZR AUCTime frame: Day 1

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Atea Study Site

    Orlando, Florida

  • Atea Study Site

    Tampa, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.